Shionogi, Inc
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Phase 3
Completed
- Conditions
- Hospital Acquired Pneumonia (HAP)Complicated Urinary Tract Infection (cUTI)Ventilator Associated Pneumonia (VAP)Healthcare-associated Pneumonia (HCAP)SepsisBloodstream Infections (BSI)
- Interventions
- Drug: Best Available Therapy
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 152
- Registration Number
- NCT02714595
- Locations
- 🇬🇧
Shionogi Research Site, London, England, United Kingdom
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 631
- Registration Number
- NCT02638337
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Phase 3
Completed
- Conditions
- ThrombocytopeniaChronic Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 215
- Registration Number
- NCT02389621
A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
Phase 2
Completed
- Conditions
- Urinary Tract Infections
- Interventions
- Drug: Imipenem/cilastatin
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 452
- Registration Number
- NCT02321800
Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 553
- Registration Number
- NCT01993940
- Locations
- 🇺🇸
Shionogi Research Site, Clarksburg, West Virginia, United States
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 547
- Registration Number
- NCT01965158
- Locations
- 🇬🇧
Shionogi Research Site, Tomairt, United Kingdom
Long Term Safety of Naldemedine
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 1246
- Registration Number
- NCT01965652
- Locations
- 🇬🇧
Shionogi Research Site, York, United Kingdom
Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis
Phase 2
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: S-555739 Dose 2Drug: S-555739 Dose 1Drug: S-555739 placebo
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 779
- Registration Number
- NCT01651871
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
Phase 3
Completed
- Conditions
- AtrophyVaginal Diseases
- Interventions
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 180
- Registration Number
- NCT01585558
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 301
- Registration Number
- NCT01586364